CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 11 05 2021
accepted: 16 07 2021
entrez: 16 8 2021
pubmed: 17 8 2021
medline: 15 12 2021
Statut: epublish

Résumé

HIV-specific CD8 T cells and broadly neutralizing antibodies (bNAbs) both contribute to the control of viremia, but in most cases, neither can completely suppress viral replication. To date, therapeutic vaccines have not been successful in eliciting HIV-specific CD8 T cell or bNAb responses that are capable of preventing long-term viral rebound upon ART cessation. These challenges suggest that a combinatorial approach that harnesses both bNAbs and CD8 T cell responses may be necessary for long term control of viral replication. In this study we demonstrate a synergistic interaction between CD8 T cells and bNAbs using an

Identifiants

pubmed: 34394110
doi: 10.3389/fimmu.2021.708355
pmc: PMC8358597
doi:

Substances chimiques

Broadly Neutralizing Antibodies 0
HIV Antibodies 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

708355

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120024
Pays : United States

Informations de copyright

Copyright © 2021 Veenhuis, Garliss, Bailey and Blankson.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Immunity. 2008 Dec 19;29(6):1009-21
pubmed: 19062316
Nat Med. 2012 Feb 19;18(3):446-51
pubmed: 22344296
Discov Med. 2010 Mar;9(46):261-6
pubmed: 20350494
AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65
pubmed: 11788027
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14
pubmed: 10694578
Curr Opin HIV AIDS. 2018 Mar;13(2):128-136
pubmed: 29266013
PLoS Pathog. 2011 Aug;7(8):e1002170
pubmed: 21829366
J Virol. 1999 May;73(5):4009-18
pubmed: 10196297
Science. 1994 Nov 11;266(5187):1024-7
pubmed: 7973652
Nat Med. 2019 Apr;25(4):547-553
pubmed: 30936546
J Virol. 1996 Feb;70(2):1100-8
pubmed: 8551569
Lancet HIV. 2016 Oct;3(10):e463-72
pubmed: 27658863
JCI Insight. 2018 Sep 20;3(18):
pubmed: 30232278
J Virol. 1994 Sep;68(9):6103-10
pubmed: 8057491
J Infect Dis. 2008 Feb 15;197(4):563-71
pubmed: 18275276
Nat Med. 2016 Apr;22(4):362-8
pubmed: 26998834
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
N Engl J Med. 2018 Aug 16;379(7):645-654
pubmed: 30110589
Nature. 2012 Nov 15;491(7424):406-12
pubmed: 23151583
J Virol. 1999 Dec;73(12):10199-207
pubmed: 10559336
Nature. 2017 Mar 23;543(7646):559-563
pubmed: 28289286
J Virol. 2008 Aug;82(15):7395-410
pubmed: 18495769
AIDS. 2019 Apr 1;33(5):773-791
pubmed: 30883388
Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91
pubmed: 29255018
Emerg Microbes Infect. 2020 Dec;9(1):194-206
pubmed: 31985356
J Virol. 2010 Feb;84(3):1439-52
pubmed: 19939925
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
N Engl J Med. 2016 Nov 24;375(21):2037-2050
pubmed: 27959728
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Sci Transl Med. 2015 Dec 23;7(319):319ra206
pubmed: 26702094
J Virol. 1999 Oct;73(10):8873-9
pubmed: 10482646
J Virol. 2014 Feb;88(4):2025-34
pubmed: 24307588
J Virol. 1995 Jul;69(7):4413-22
pubmed: 7769703
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
Nature. 2013 Nov 14;503(7475):277-80
pubmed: 24172896
Nature. 2014 Oct 30;514(7524):642-5
pubmed: 25119033
J Exp Med. 2021 Jan 4;218(1):
pubmed: 32966579
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43
pubmed: 1384050
Curr Opin HIV AIDS. 2018 Sep;13(5):408-415
pubmed: 29957615
Nat Med. 2018 May;24(5):610-616
pubmed: 29662199
Cell. 2014 Aug 28;158(5):989-999
pubmed: 25131989
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
pubmed: 7520721
J Virol. 1994 Aug;68(8):4821-8
pubmed: 7518527
J Virol. 2000 Nov;74(21):10074-80
pubmed: 11024136
J Virol. 2007 Apr;81(7):3465-76
pubmed: 17251286
N Engl J Med. 2019 Apr 18;380(16):1535-1545
pubmed: 30995373
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
pubmed: 17428922
Nature. 2018 Sep;561(7724):479-484
pubmed: 30258136
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Nature. 2018 Nov;563(7731):360-364
pubmed: 30283138
Retrovirology. 2014 Oct 02;11:83
pubmed: 25700025
Front Immunol. 2020 May 06;11:823
pubmed: 32435247
J Virol. 2012 Dec;86(24):13679-88
pubmed: 23055552
Nature. 2016 May 5;533(7601):105-109
pubmed: 27120156
Nat Med. 2020 Feb;26(2):222-227
pubmed: 32015556
J Virol. 2019 Jan 17;93(3):
pubmed: 30404799
J Virol. 2001 Dec;75(24):12198-208
pubmed: 11711611
PLoS Pathog. 2011 Feb;7(2):e1002002
pubmed: 21383976
J Virol. 2005 Feb;79(4):2199-210
pubmed: 15681422
Sci Transl Med. 2017 Sep 20;9(408):
pubmed: 28931655
Nat Med. 2017 Feb;23(2):185-191
pubmed: 28092665
J Virol. 1994 Jul;68(7):4650-5
pubmed: 8207839
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Nature. 2012 Dec 6;492(7427):118-22
pubmed: 23103874
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7
pubmed: 1719545

Auteurs

Rebecca T Veenhuis (RT)

Department of Molecular and Comparative Pathobiology, Johns Hopkins Medicine, Baltimore, MD, United States.

Caroline C Garliss (CC)

Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.

Justin R Bailey (JR)

Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.

Joel N Blankson (JN)

Department of Molecular and Comparative Pathobiology, Johns Hopkins Medicine, Baltimore, MD, United States.
Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH